Saturday, May 23, 2015

ROTH starts Vascular Biogenics at buy

ROTH starts Vascular Biogenics at buy

May 22, 2015 by · Leave a Comment 

Tweet ROTH Capital Partners has initiated coverage of Vascular Biogenics (NASDAQ:VBLT) with a “buy” rating and a $13 price target. The stock closed at $5.05 on Thursday. Vascular has two technology platforms targeting oncology and immunology indications. The first platform is Vascular Targeting System (VTS), which is a multi-component gene therapy design targeting vascular endothelial […]

Amarantus in capital restructuring to up-list shares

Amarantus in capital restructuring to up-list shares

May 22, 2015 by · Leave a Comment 

Tweet Amarantus BioSciences Holdings (OTCQB:AMBS) has implemented a 1-for-150 reverse stock split of its common stock to facilitate listing its shares on a national exchange this year. Trading on a split-adjusted basis will occur on final approval from the Financial Industry Regulatory Authority (FINRA). Following FINRA approval, the company’s common stock will temporarily trade on […]

Response Biomedical promotes COO Kinnaird to CEO

Response Biomedical promotes COO Kinnaird to CEO

May 20, 2015 by · Leave a Comment 

Tweet Response Biomedical (OTCBB:RPBIF; TSX:RBM) has promoted COO, Dr. Barbara Kinnaird, to the position of CEO, effective immediately, succeeding interim CEO, Dr. Anthony Holler. “Since her promotion to COO in September 2014, Dr. Kinnaird has successfully led Response through a series of strategic moves to position the company for future growth exemplified by the recently […]

GeneNews in pact to increase stake in IDL venture

GeneNews in pact to increase stake in IDL venture

May 19, 2015 by · Leave a Comment 

Tweet GeneNews (TSX:GEN) has entered into a purchase agreement with Cobalt Healthcare Consultants to purchase Health Diagnostic Laboratory’s (HDL) one-third ownership stake in their Innovative Diagnostic Laboratory (IDL) joint venture for $4-million. Combined with prior investments in IDL, GeneNews and Cobalt will each own a 50% equity interest in the joint venture. GeneNews and Cobalt […]

HCW starts StemCells at buy

HCW starts StemCells at buy

May 18, 2015 by · Leave a Comment 

Tweet H.C. Wainwright has launched coverage of StemCells (NASDAQ:STEM) with a “buy” rating and using a discounted cash flow analysis to derive a price target of $1. The stock closed at 62 cents on Friday. StemCells is focused on applying its human CNS stem cells platform to develop treatments for CNS disorders. The company’s platform […]

Cynapsus files for NASDAQ listing, offering, stock rollback

Cynapsus files for NASDAQ listing, offering, stock rollback

May 15, 2015 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX:CTH) has filed a registration statement with the SEC for a public offering of common stock in the U.S. and has filed an application to list on the NASDAQ Capital Market. The timing, number of shares and price per share of the proposed offering have not yet been determined. Cynapsus also […]

Microbix Q2 revenue climbs 23%

Microbix Q2 revenue climbs 23%

May 15, 2015 by · Leave a Comment 

Tweet Microbix Biosystems (TSX:MBX) has reported revenue of $2.5-million in the fiscal second quarter, ended March 31, 2015, an increase of 23% over $2.1-million in last year’s second quarter. Revenue was made up entirely of virology products, with the improvement mainly attributable to increased sales of the company’s core antigen products. To a lesser extent, […]

Amarantus posts positive PD preclinical data with MANF

Amarantus posts positive PD preclinical data with MANF

May 15, 2015 by · Leave a Comment 

Tweet Amarantus BioScience Holdings (OTCQB:AMBS) has completed a study of MANF (mesencephalic-astrocyte-derived neurotrophic factor) administration to the putamen and the substantia nigra of pigs by convection-enhanced delivery. The study generated MANF brain delivery and distribution data, further supporting the rationale for MANF’s development in the treatment of Parkinson’s disease (PD). The study was conducted in […]

Janney starts Advaxis at buy

Janney starts Advaxis at buy

May 15, 2015 by · Leave a Comment 

Tweet Janney Capital Markets has initiated coverage of Advaxis (NASDAQ:ADXS) with a “buy” rating and fair value estimate of $26. The stock closed at $18.97 on Thursday. Advaxis is built on immunotherapy technology, which utilizes bacteria to stimulate an immune attack on cancer cells. The company is developing candidates for the treatment of HPV-associated cancers, […]

GeneNews IDL JV test volume up 150% in Q1

GeneNews IDL JV test volume up 150% in Q1

May 14, 2015 by · Leave a Comment 

Tweet GeneNews’ (TSX:GEN) U.S. joint venture, Innovative Diagnostic Laboratory (IDL), carried out a total of 39,500 tests in the first quarter this year, up about 150%, from 15,800 in the year earlier quarter. In a statement, James Howard-Tripp, executive chairman of GeneNews, said that with vital functions at IDL successfully brought in-house, “we remain committed […]

Next Page »

Email Newsletters with Constant Contact
Google+